The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas

Highlights ► We constructed and utilized a computer simulation model to evaluate the economic value of a CL vaccine. ► Modest protection duration and efficacy are required for CL vaccination to cost less than treatment. ► A preventative CL vaccine could save costs at moderate levels of infection ris...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2013-01, Vol.31 (3), p.480-486
Hauptverfasser:	Bacon, Kristina M, Hotez, Peter J, Kruchten, Stephanie D, Kamhawi, Shaden, Bottazzi, Maria Elena, Valenzuela, Jesus G, Lee, Bruce Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Americas - epidemiology Antigens Applied microbiology Biological and medical sciences Bolivia Brazil chaparral Chemotherapy Colombia Computer Simulation cost effectiveness Costs and Cost Analysis Cutaneous leishmaniasis deforestation Drug dosages drug therapy economic valuation Economics Ecuador Endemic Diseases - economics Endemic Diseases - prevention & control Fundamental and applied biological sciences. Psychology Health risks Humans Infections Latin America Leishmaniasis Vaccines - administration & dosage Leishmaniasis Vaccines - economics Leishmaniasis Vaccines - immunology Leishmaniasis, Cutaneous - economics Leishmaniasis, Cutaneous - epidemiology Leishmaniasis, Cutaneous - prevention & control Mexico Microbiology Parasites Parasitic diseases Peru Sand & gravel Skin Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vector-borne diseases Venezuela
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights ► We constructed and utilized a computer simulation model to evaluate the economic value of a CL vaccine. ► Modest protection duration and efficacy are required for CL vaccination to cost less than treatment. ► A preventative CL vaccine could save costs at moderate levels of infection risk.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2012.11.032